NCT07112170 Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma
| NCT ID | NCT07112170 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Metastatic Melanoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2025-07-24 |
| Primary Completion | 2027-07-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2025-07-24 with a primary completion date of 2027-07-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This open-label, prospective, single-arm Phase II trial explores whether adding stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy to oligoprogressive lesions can help delay disease progression in patients with metastatic melanoma. Participants may have up to ten extracranial oligoprogressive sites, with no upper limit on the total number of metastatic lesions. The study aims to assess whether targeting these progressing sites with focused radiotherapy can extend progression-free survival in this patient population.
Eligibility Criteria
Inclusion Criteria: * Age 18 or older * ECOG 0-2 * Willing and able to provide informed consent * Metastatic melanoma detected on imaging and clinically confirmed. * Treated with first line immunotherapy or BRAF inhibitors. * No upper limit to the number of total metastatic sites, but a maximum of ten progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extra cranial. * Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll. * All sites of oligoprogression that can be safely treated with SBRT or hypofractionated radiotherapy. Exclusion Criteria: * \>10 extracranial sites of progressive disease. * Pregnancy. * Leptomeningeal disease. * Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma. * Prior radiotherapy near the oligoprogressive lesion precluding SBRT or hypofractionated radiotherapy due to exceeding OAR tolerance. * Any psychological, sociological or geographical issue potentially hampering compliance with the study. * Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07112170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07112170 currently recruiting?
Yes, NCT07112170 is actively recruiting participants. Contact the research team at jillian.tsai@uhn.ca for enrollment information.
Where is the NCT07112170 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07112170 clinical trial?
NCT07112170 is sponsored by University Health Network, Toronto. The trial plans to enroll 52 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.